Skip to main content
CareerCircle Home
Log in
Join
Search for and find Director, Clinical Science jobs and Daiichi Sankyo jobs at CareerCircle.com
Daiichi Sankyo jobs, learn more at CareerCircle.com

Director, Clinical Science

Daiichi Sankyo

Posted Friday, May 9, 2025

Posting ID: R4241

Remote | Remote by Design Home Office,
Share:
FacebookTwitterLinkedin
Join a Legacy of Innovation 125 Years and Counting!

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 125 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 18,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group's 2025 Vision to become a Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.

Job Summary:

Oversees one or more trials of medium to high complexity in design and geographic scope. Such trials could be pivotal for submission; Prepares clinical section of regulatory documents; Oversees management and performance of CRO; Participates in creation of developmental and regulatory strategy; Drafts protocol profiles and sections of key submission documents; Point of contact for interactions with regulatory-agency clinical reviewing divisions on clinical matters; Represents Clinical Development in Project Teams, possibly as Global Clinical Lead.

Responsibilities:
  • Study Strategy: Clinical study leader (CSL) or major scientific/medical contributor; For large or complex Phase 2 studies: Provides the strategic direction to BD&O for EDC, edit checks, data quality listings, SAP, DM plan, Reviews patient population and protocol compliance for consistency with study strategy, Develops biomarker strategy in collaboration with TMCP, Collaborates with external KOLs to refine study plans; Prepares and participate in regulatory agency meetings, if applicable
  • Study Planning and Execution: As CSL for Phase 2 studies: Provides input on major milestones of trial, clinical trial plan and contingency planning, Analyzes, updates management on potential risks to study deliverables, Provides input on ICF creation, Oversees recruitment, retention; establishes and implement contingency plans for shortfalls, Consults & recruits members for DSMB and/or adjudication committee setup; Interacts with KOLs and PIs to plan study and monitor completion
  • Study Outputs: For Phase 2 studies: Drafts responses to IRBs and HA, Collaborates with TMCP to ensure appropriate biomarker, PK / PD measurements, Reviews emerging clinical data regularly, Leads dose-escalation meetings, Performs quality assessment with delivery lead e.g. review TLG before DBL, and quality check of data, Works with BD&O to ensure SAP updates; Responsible for valid clinical interpretation of study results as Clinical Study Leader, medical monitor or regional clinical/Translational Medicine and Clinical Pharmacology representative
  • External Collaboration: Develops and leads external advisory panels to advise on Phase 2 study strategy, design, and conduct; Interacts with KOLs for indication specific advice; Leads broad collaboration with KOLs or major institution, e.g. NCI.
  • Scientific, Program Related: Integrated Study Team (IST) representative: Creates early development plan and contributes to overall development Strategy; Develops program biomarker strategy; Achieves endorsement for plan by function and team; Interprets and react accordingly to new preclinical/clinical data (e.g.; Go/No Go decisions, reprioritization, etc.); Operational Project Team (OPT) leader; Responsible before the IST for the creation and execution of development strategy for a program
  • Additional non-study related activities: Initiates contact w/KOL and prepare material for KOL interactions on a program-based need; Peripheral involvement in Business Development activities for late-stage compounds Involvement with in-licensing and acquisitions on individual due diligence activities; Contributor to portfolio decisions
Qualifications: Successful candidates will be able to meet the qualifications below with or without a reasonable accommodation.

Education:
  • Master's Degree or equivalent preferred
  • PharmD or equivalent preferred
  • PhD or equivalent preferred
  • Postgraduate training in TA or related specialty, or equivalent preferred
Experience:
  • 7 or More Years with PharmD, PhD and relevant clinical experience preferred
  • 10 or More Years with Master's degree and relevant clinical experience preferred
Travel:
  • Ability to travel up to 30% In-house office position that may require travel (global).
Daiichi Sankyo, Inc. is an equal opportunity/affirmative action employer. Qualified applicants will receive consideration for employment without regard to sex, gender identity, sexual orientation, race, color, religion, national origin, disability, protected veteran status, age, or any other characteristic protected by law.

The company is an equal opportunity employer and will consider all applications without regards to race, sex, age, color, religion, national origin, veteran status, disability, sexual orientation, gender identity, genetic information or any characteristic protected by law.
On-Site
Planning
Oncology
Pharmaceuticals
Leadership
Management
Clinical Trials
Business Development
Innovation
Research
Adjudication
Due Diligence
Milestones (Project Management)
SAP Applications
Immune Disorder
Data Quality
Pre-Clinical Development
Key Opinion Leader Development
Electronic Data Capture (EDC)
Biomarkers
Regulatory Documents
Clinical Experience
Clinical Trial Planning
Clinical Pharmacology
Pharmacodynamics
Pharmacokinetics
Quality Assessment
Contingency Planning
Translational Medicine
Mergers And Acquisitions

Blog